Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Morand EF, Vital EM, Petri M, van Vollenhoven R, et al. Lancet 2023 Feb 24:S0140-6736(22)02607-1. doi: 10.1016/S0140-6736(22)02607.

Read + Share

Amedeo Smart

Independent Medical Education

Morand EF, Vital EM, Petri M, van Vollenhoven R, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet 2023 Feb 24:S0140-6736(22)02607-1. doi: 10.1016/S0140-6736(22)02607.
PMID: 36848918